News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
FDA approved Bristol Myers Squibb’s Opdivo + Yervoy for first-line treatment of MSI-H/dMMR metastatic colorectal cancer
Bristol Myers Squibb/bms.com
May 10, 2025, 17:01

FDA approved Bristol Myers Squibb’s Opdivo + Yervoy for first-line treatment of MSI-H/dMMR metastatic colorectal cancer

Fight Colorectal Cancer shared a post on LinkedIn:

“Congratulations to Bristol Myers Squibb on the FDA approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for first-line treatment of patients with MSI-H/dMMR metastatic Colorectal Cancer!
This milestone marks a major advancement in immunotherapy for colorectal cancer, offering a powerful option for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors-an important subset of the CRC population.
At Fight CRC, we believe every colorectal cancer patient deserves access to comprehensive biomarker testing from the moment of diagnosis. Approvals like this one reinforce the value of identifying MSI-H/dMMR status early so patients can benefit from treatments that are matched to their tumor biology.”

Read more about Opdivo + Yervoy here.

Learn more about FDA and colorectal cancer on OncoDaily.

Bristol Myers Squibb cancer colorectal cancer FDA Fight Colorectal Cancer ipilimumab nivolumab OncoDaily Oncology Opdivo Yervoy
Special Coverage
Blog
Jul 9, 2025, 15:26
Eva Zopf: 10-Minute Survey on Healthcare Professionals' Views on Exercise and ICI Therapy
Blog
Jul 9, 2025, 15:16
ICML’s Serendipitous Origins as a Leading Global Event in the Field of Malignant Lymphomas - ESO
Career
Jul 9, 2025, 15:13
Antonio Giordano Has Officially Joined Italy’s Higher Health Council as Vice President of Section - SHRO
Blog
Jul 9, 2025, 15:04
Jay Bhattacharya: New NIH Policy to Cap What Publishers Can Charge NIH-Supported Scientists
Science
Jul 9, 2025, 15:01
Gil Awada: How Neoadjuvant Immunotherapy is Reshaping the Treatment Landscape Across Solid Tumours
Blog
Jul 9, 2025, 15:00
Sarah Scagliarini: Wind of Hope for Our Patients with Renal Cell Carcinoma...
Blog
Jul 9, 2025, 14:52
Nicholas P Restifo: Remembering a Kind Mentor and Pioneer of CAR T-Cell Therapy - Zelig Eshhar
Career
Jul 9, 2025, 14:44
David Planchard: The Departure of a Genito-Urinary Oncology Giant, Karim Fizazi, from Gustave Roussy
Oncolibrary
Jul 9, 2025, 14:30
New Paper Alert: STAMPEDE Trial Results on Metformin in Metastatic Prostate Cancer Treatment
Blog
Jul 9, 2025, 14:24
How Uncertainty Can Be Used to Catch Out-of-Distribution Cases in Auto-Segmentation - ESTRO
Blog
Jul 9, 2025, 14:14
Yan Leyfman: Can Macrophages Revolutionize Cancer Immunotherapy?
Blog
Jul 9, 2025, 14:02
UICC and ISOPP Call for Better Quality and Safety at Every Level of the Supply Chain to Protect Patients